Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/849"
| Predicate | Value (sorted: none) |
|---|
| rdf:type |
|
| rdf:type |
|
| rdfs:label |
|
| ?:Evidence_type |
|
| ?:Evidence_enzyme_system |
|
| dc:creator |
|
| dc:date |
|
| ?:content |
"route of administration: oral
study duration: "Study 1 was conducted in 2 distinct periods separated by a 7-day washout. In period 1, a single 50-mg dose of desipramine was administered, and blood samples were obtained for the measurement of desipramine plasma concentrations immediately before the dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours after dosing. In period 2, duloxetine was administered at an initial dose of 40 mg twice daily. Subjects who did not tolerate this dose were allowed to have the dose lowered to 20 mg twice daily for up to 5 doses, after which dosing at 40 mg twice daily was resumed. On the seventh day of duloxetine dosing (day 14 of the overall protocol), the dose was increased to 60 mg twice daily and was continued at that level for an additional 14 days. On day 21 of the overall protocol (day 8 of duloxetine 60 mg twice daily dosing), a 50-mg dose of desipramine was administered. Blood samples were drawn to determine desipramine plasma concentrations as described for period 1, with additional samples at 168 and 192 hours after the desipramine dose. On the day before and the day of the period 2 desipramine dose (protocol days 20 and 21), blood samples for the measurement of duloxetine plasma concentrations were drawn immediately before duloxetine administration and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after administration."
population: 14 healthy, non-smoking, adults; 7 male, 7 female; nearly all were of apparent European decent ("white")
tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.
ages: 21 - 63
description:
"Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold.""
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ duloxetine_does_not_inhibit_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1066 }
Context graph
